Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
Latest Information Update: 17 Sep 2021
At a glance
- Drugs High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms QUILT-3.028
- Sponsors ImmunityBio
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 10 May 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Results published in the Media Release